Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 3 5 IN DEXTROSE 25 IN PLASTIC CONTAINER versus TRAVASOL 10 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 3 5 IN DEXTROSE 25 IN PLASTIC CONTAINER versus TRAVASOL 10 IN PLASTIC CONTAINER.
AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER vs TRAVASOL 10% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn II 3.5% in Dextrose 25% is a combination of amino acids and dextrose for parenteral nutrition. Amino acids provide nitrogen and essential substrates for protein synthesis, while dextrose provides a caloric source to prevent protein catabolism. The mechanism involves infusion into the bloodstream, bypassing gastrointestinal digestion, to maintain or restore nitrogen balance and provide energy.
Travasol 10% (amino acids injection) provides essential and non-essential amino acids for protein synthesis and nitrogen equilibrium in patients unable to obtain adequate nutrition orally or enterally. Amino acids are building blocks for proteins; they also serve as substrates for gluconeogenesis and other metabolic pathways.
Intravenous infusion. Amino acid dose based on protein requirements: 0.8-1.0 g/kg/day for stable patients, up to 1.5-2.0 g/kg/day for catabolic states. Dextrose dose based on caloric needs: typically 150-300 g/day. Infuse via central line at rates not exceeding 0.5 g/kg/hour dextrose. Typical starting rate: 50-100 mL/hr, titrated based on metabolic tolerance.
Intravenous infusion: 500 mL to 2 L per day, administered at a rate not exceeding 4 mL/kg/h. Typical adult dose is 1-2 g protein/kg/day (equivalent to 10-20 mL/kg/day of 10% solution). Rate and volume are adjusted based on patient's metabolic needs and clinical status.
None Documented
None Documented
Amino acids have variable half-lives (minutes to hours); dextrose has a plasma half-life of ~2 hours under euglycemic conditions. Clinically, continuous infusion maintains steady state.
Not applicable as a single entity; constituent amino acids have half-lives varying from minutes to hours (e.g., 10-30 min for most). Clinical context: continuous infusion maintains steady state.
Renal excretion of amino acids as urea and ammonia; dextrose is metabolized to CO2 and water. Approximately 90% of infused amino nitrogen is recovered in urine as urea within 24 hours. Dextrose is completely metabolized.
Renal excretion of infused amino acids and their metabolites; excess nitrogen excreted as urea in urine. ~90-95% of infused amino acids are utilized or excreted renally. Fecal excretion negligible.
Category C
Category C
Amino Acid Solution
Amino Acid Solution